Open AccessReal-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months
Author(s) -
Moritz Z. Kayser,
Nora Drick,
Katrin Milger,
Jan Fuge,
Nikolaus Kneidinger,
Stephanie Korn,
Roland Buhl,
Jürgen Behr,
Tobias Welte,
Hendrik Suhling
Publication year - 2021
Publication title -
journal of asthma and allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.162
H-Index - 30
ISSN - 1178-6965
DOI - 10.2147/jaa.s319572
Subject(s) - mepolizumab , benralizumab , medicine , exacerbation , asthma , interquartile range , exhaled nitric oxide , gastroenterology , immunology , eosinophil , bronchoconstriction
Treatment of severe eosinophilic asthma (SEA) has been revolutionized by the development of monoclonal antibodies targeting underlying immunological pathways of eosinophilic asthma. Two of the most frequently used antibodies in clinical practice are mepolizumab, targeting interleukin (IL) 5 and benralizumab, targeting the IL5 receptor alpha. The comparative treatment efficacy of these antibodies remains unclear, particularly regarding long-term outcomes.